Cholesterol trafficking

Cholesterol trafficking is the tightly regulated cellular process by which cholesterol is transported between organelles, including the plasma membrane, endoplasmic reticulum, Golgi apparatus, endosomes, lysosomes, and lipid droplets[1][2][4][5][6][7]. This process maintains cellular cholesterol homeostasis, prevents toxic accumulation, and enables cholesterol-dependent signaling and membrane maintenance. It involves receptor-mediated uptake (e.g., LDL receptor), lysosomal processing (NPC1, NPC2), nonvesicular transport via lipid transfer proteins (OSBP, LTPs), and regulatory control through transcription factors (SREBPs, LXRs)[1][2][4][5]. Defects in cholesterol trafficking pathways cause diseases such as Niemann-Pick disease type C and contribute to metabolic and cardiovascular disorders[1][6]. Drugs target various components of cholesterol trafficking pathways, but the process itself is not a singular molecular therapeutic target.

Other names

Cholesterol transportIntracellular cholesterol traffickingNonvesicular cholesterol transportCholesterol movement between organelles

Mechanisms of action related to modulating cholesterol trafficking include inhibition of cholesterol synthesis (e.g., statins reducing HMGCR activity and regulating SREBP2), blockade or facilitation of cholesterol movement between organelles (e.g., HPβCD, OSBP modulators), enhancement of cholesterol efflux (e.g., LXR agonists increasing ABCA1 and ABCG1 function), and modulation of lysosomal cholesterol release (e.g., via NPC1/NPC2 function enhancement or mimetic drugs).